OPDYTA (Nivolumab)-100mg

Opdyta (Nivolumab) is a human programmed death receptor-1 (PD-1) blocking antibody.

Opdyta is used;

  • For the treatment of patients with unresectable or metastatic melanoma and disease progression in combination with ipilimumab and, if BRAF V600 mutation-positive, a BRAF inhibitor.
  • For the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy. Or in combination with ipilimumab as a first-line treatment whose tumors express PD-L1, with no EGRF or ALK genomic tumor abnormalities.
  • Treatment of advanced renal cell cancer in patients who have received prior anti-angiogenic therapy. Or in combination with Ipilimumab.
  • Treatment of patients with classical Hodgkins lymphoma (cHL) that has relapsed or progressed after autologous hematopoietic stem cell transplantation (HSCT) and post-transplantation brentuximab vedotin.
    Treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) with disease progression on or after platinum-based therapy.
  • Treatment of locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy.
    Treatment of metastatic small cell lung cancer (SCLC) with progression after platinum-based chemotherapy and at least one other line of therapy.
  • For the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient solid tumors or colorectal cancer that have progressed following prior treatment.
  • For the treatment of patients with hepatocellular cancer (HCC) who have been previously treated with sorafenib.
  • For patients with unresectable advanced, recurrent, or metastatic esophageal squamous cell carcinoma (ESCC) after prior fluoropyrimidine- and platinum-based chemotherapy
Enquiry Now

Additional information

Trade Name


Generic Name



Bristol-Myers Squibb


non-small cell lung cancer, kidney cancer, head and neck cancer, melanoma, Hodgkin's disease, and liver cancer.

Doasage Form



1 x 10m/ml